Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia.

Authors :: Mori N
Katayama M
Nukaga S
Source :: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi [J Microbiol Immunol Infect] 2021 Feb; Vol. 54 (1), pp. 109-112. Date of Electronic Publication: 2020 Oct 05.
Publication Year :: 2021
Abstract: No specific therapy is available for COVID-19. We report the effectiveness and adverse effects of triple therapy with hydroxychloroquine, azithromycin, and ciclesonide in patients with COVID-19 pneumonia. The clinical condition of the patients improved within 5 days in response to the therapy.<br />Competing Interests: Declaration of competing interest All authors do not have any conflicts of interest to declare.<br /> (Copyright © 2020. Published by Elsevier B.V.)

Subjects :: Aged
COVID-19 epidemiology
Drug Therapy, Combination
Female
Humans
Liver drug effects
Male
Middle Aged
SARS-CoV-2 drug effects
Tokyo epidemiology
Antiviral Agents therapeutic use
Azithromycin therapeutic use
Hydroxychloroquine therapeutic use
Pregnenediones therapeutic use
COVID-19 Drug Treatment

Language :: English
ISSN :: 1995-9133
Volume :: 54
Issue :: 1
Database :: MEDLINE
Journal :: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
Publication Type :: Academic Journal
Accession number :: 33054978
Full Text :: https://doi.org/10.1016/j.jmii.2020.09.003

Full Text Access

Tools